

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:

Confluence Life Sciences, Inc.
4320 Forest Park Avenue
Suite 303
St. Louis, MO 63108

2. NRC/REGIONAL OFFICE

Region III
U. S. Nuclear Regulatory Commission
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4352

REPORT NUMBER(S) 12-01

3. DOCKET NUMBER(S)

030-38464

4. LICENSE NUMBER(S)

24-32829-01

5. DATE(S) OF INSPECTION

February 3, 2012

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:



- ☒ 1. Based on the inspection findings, no violations were identified.
- ☐ 2. Previous violation(s) closed.
- ☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, to exercise discretion, were satisfied.

Non-cited violation(s) were discussed involving the following requirement(s):

- ☐ 4. During this inspection, certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited in accordance with NRC Enforcement Policy. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.
(Violations and Corrective Actions)

Statement of Corrective Actions

I hereby state that, within 30 days, the actions described by me to the Inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

TITLE	PRINTED NAME	SIGNATURE	DATE
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert P. Hays		2/3/12
BRANCH CHIEF	Tamara E. Bloomer		2/17/12

Docket File Information

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED: Confluence Life Sciences, Inc. 4320 Forest Park Avenue Suite 303 St. Louis, MO 63108 REPORT NUMBER(S) 12-01		2. NRC/REGIONAL OFFICE Region III U. S. Nuclear Regulatory Commission 2443 Warrenville Road, Suite 210 Lisle, IL 60532-4352	
3. DOCKET NUMBER(S) 030-38464	4. LICENSE NUMBER(S) 24-32829-01	5. DATE(S) OF INSPECTION February 3, 2012	
6. INSPECTION PROCEDURES USED 87134	7. INSPECTION FOCUS AREAS 03.01-03.07		

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S) 03620	2. PRIORITY 5	3. LICENSEE CONTACT Jeff Hirsch, RSO	4. TELEPHONE NUMBER (314) 932-4032
-----------------------------	------------------	---	---------------------------------------

☒ Main Office Inspection Next Inspection Date: 02/03/2017

☐ Field Office Inspection

☐ Temporary Job Site Inspection

PROGRAM SCOPE

This was the initial inspection after the license was issued on August 31, 2011. The licensee is authorized by the license to use various isotopes for research and development as defined by Section 30.4 of 10 CFR Part 30, including in-vitro studies. At the time of the inspection, the licensee had 4 individuals authorized to use licensed material, but only two had used licensed material since the license was issued. Licensed activities were initiated on September 21, 2011, and the licensee has received two shipments of H-3. The licensee has no plans to sewer any waste.

Performance Observations

During the inspection, the RSO and authorized user demonstrated/discussed: (1) survey meter use and calibrations; (2) package ordering, receiving, and check-in procedures; (3) area and contamination surveys; (4) waste handling, storage and disposal procedures; (6) unsealed isotope inventory control; (7) security of licensed material and access to the research lab; (8) minor contamination events (none); (9) staff training; and (10) records of receipt, use, and waste. Area surveys of the waste storage and lab areas did not reveal any contamination or elevated readings.